Clinical trialNCT04981509RecruitingPhase 2Interventional

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

SponsorNational Cancer Institute (NCI)Enrollment65Hereditary Leiomyomatosis and Renal Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell CarcinomaSporadic Papillary Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ramaprasad Srinivasan
National Cancer Institute LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Uc San Diego Moores Cancer Center
La Jolla, California, United States
Suspended
Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
Suspended
Emory University Hospital Midtown
Atlanta, Georgia, United States
Suspended
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Suspended
Northwestern University
Chicago, Illinois, United States
Suspended
Nci - Center for Cancer Research
Bethesda, Maryland, United States
Ramaprasad Srinivasan
Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Suspended
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Suspended
Nyu Langone Hospital - Long Island
Mineola, New York, United States
Active, not recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Active, not recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Suspended
University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
Suspended
Ut Md Anderson Cancer Center
Houston, Texas, United States
Suspended

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Bevacizumab →Erlotinib →Sodium fluoride →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Jun 2022
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 8 Jul 2026
Registered enrollment: 65
Registry id: NCT04981509

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.